13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
28 檔
75.6%
The Q4 2025 SEC filing reveals that EcoR1 Capital, LLC held a total portfolio value of $2.1B, covering 28 public equity positions.
EcoR1 Capital, LLC executed strategic sector rebalancing during Q4 2025, establishing 9 new positions while fully exiting 11 holdings and trimming 3 positions.
In terms of portfolio concentration, the top 5 core holdings (including ZYME, ANAB, JAZZ) accounted for 75.6% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc | Stock-Other | 27.44% | +4.78% | — | |
| 2 | ANAB | Anaptysbio Inc | Stock-Other | 17.33% | +7.31% | — | |
| 3 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 13.16% | -13.69% | EXIT | |
| 4 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 9.06% | -6.61% | EXIT | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.53% | -10.81% | EXIT | |
| 6 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 3.31% | +0.88% | — | |
| 7 | MBX | Mbx Biosciences Inc | Stock-Other | 3.04% | +0.06% | — | |
| 8 | IMNM | Immunome Inc | Stock-Other | 2.78% | — | -30.00% | |
| 9 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.50% | -0.08% | — | |
| 10 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 2.47% | +0.31% | — | |
| 11 | XNCR | Xencor Inc | Stock-Other | 2.31% | -1.12% | EXIT | |
| 12 | CGON | Cg Oncology Inc | Stock-Other | 2.01% | +3.93% | — | |
| 13 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.60% | -0.02% | — | |
| 14 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 1.56% | +1.55% | — | |
| 15 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.30% | +0.31% | — | |
| 16 | NGNE | Neurogene Inc | Stock-Other | 1.19% | +0.85% | — | |
| 17 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 18 | PCVX | Vaxcyte Inc | Stock-Other | 0.94% | — | — | |
| 19 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.77% | — | — | |
| 20 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.71% | — | +497.17% | |
| 21 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.47% | +0.85% | — | |
| 22 | MNKD | Mannkind CORP | Stock-Other | 0.43% | — | — | |
| 23 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.39% | — | — | |
| 24 | EOLS | Evolus Inc | Stock-Other | 0.20% | — | — | |
| 25 | IBIO | Ibio Inc | Stock-Other | 0.20% | -0.13% | EXIT | |
| 26 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.15% | -0.17% | — | |
| 27 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 0.09% | — | — | |
| 28 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | -93.33% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc | +8.6% | — | Unchanged |
| 2 | ANAB | Anaptysbio Inc | +5.8% | — | Unchanged |
| 3 | 260 | Centessa Pharmaceuticals-adr | +2.9% | +466.36% | Add |
| 4 | JAZZ | Jazz Pharmaceuticals plc | +2.4% | — | Unchanged |
| 5 | MBX | Mbx Biosciences Inc | +1.3% | — | Unchanged |
| 6 | VYGR | Voyager Therapeutics Inc | +0.6% | +497.17% | Add |
| 7 | CRNX | Crinetics Pharmaceuticals In | +0.5% | — | Unchanged |
| 8 | IMNM | Immunome Inc | +0.5% | -30.00% | Trim |
| 9 | NUVB-WS | Nuvation Bio Inc -cw27 | +0.2% | — | Unchanged |
| 10 | NGNE | Neurogene Inc | +0.1% | — | Unchanged |
| 11 | ATRA | Atara Biotherapeutics Inc | +0.1% | — | Unchanged |
| 12 | AQST | Aquestive Therapeutics Inc | +0.1% | — | Unchanged |
| 13 | BBOT | Bridgebio Oncology Therapeut | 0% | — | Unchanged |
| 14 | SRZNW | Surrozen Inc-cw25 | 0% | -93.33% | Trim |
| 15 | LKFT | Lakefront Biotherapeutic-adr | -0.3% | — | Unchanged |
| 16 | ETON | Eton Pharmaceuticals Inc | -0.6% | — | Unchanged |
| 17 | CRSP | CRISPR Therapeutics AG | -1% | — | Unchanged |
| 18 | XNCR | Xencor Inc | -1.2% | -45.99% | Trim |
| 19 | ORIC | Oric Pharmaceuticals Inc | -1.4% | — | Unchanged |
| 20 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 21 | TNGX | Tango Therapeutics Inc | — | EXIT | Sold out |
| 22 | APLSUSD | Apellis Pharmaceuticals Inc | — | EXIT | Sold out |
| 23 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 24 | MDGL | Madrigal Pharmaceuticals Inc | — | EXIT | Sold out |
| 25 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 26 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 27 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 28 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 29 | ALKS | Alkermes plc | — | EXIT | Sold out |
| 30 | ✓ | — | EXIT | Sold out | |
| 31 | MNKD | Mannkind CORP | — | NEW | New buy |
| 32 | PRME | Prime Medicine Inc | — | EXIT | Sold out |
| 33 | KURA | Kura Oncology Inc | — | EXIT | Sold out |
| 34 | EOLS | Evolus Inc | — | NEW | New buy |
| 35 | IBIO | Ibio Inc | — | NEW | New buy |
| 36 | PEPG | Pepgen Inc | — | EXIT | Sold out |
| 37 | MREO | Mereo Biopharma Group Pl-adr | — | NEW | New buy |
| 38 | CAMP | Camp4 Therapeutics CORP | — | NEW | New buy |
| 39 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 28 disclosed positions in Q4 2025.
During Q4 2025, EcoR1 Capital, LLC's top holdings by market value included ZYME (27.4%)、ANAB (17.3%)、JAZZ (13.2%). The largest single position, ZYME, represented 27.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CGON
市值: $44.2M
Top Position Liquidated / Trimmed
QURE
前期市值: $232.8M
In Q4 2025, EcoR1 Capital, LLC made 25 total portfolio adjustments, initiating 9 new buys, adding to 2 positions, trimming 3 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.